XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

Buprenorphine Extended-release in Jail and at Re-entry: Open-label Randomized Controlled Trial vs. Daily Sublingual Buprenorphine-naloxone

This is a pilot proof-of-concept randomized controlled trial, open-label and unblinded, examining the feasibility and acceptability of Buprenorphine extended-release vs. daily sublingual buprenorphine-naloxone for the treatment of opioid use disorder in jail and at community re-entry.

Inclusion Criteria:

• Adults >18yo incarcerated in NYC jails with known release dates.
• DSM-V criteria for current opioid use disorder (DSM-IV opioid dependence).
• Currently maintained on sublingual buprenorphine-naloxone in the NYC jail opioid treatment program.

Exclusion Criteria:

• Individual not interested in XRB treatment. Current SLB patients are otherwise by definition appropriate for XRB.
• Pregnant or planning conception. A urine dipstick pregnancy (hCG) test will be administered at baseline. The test detects human chorionic gonadotropin (hCG) in urine with a sensitivity/specificity of: 25 mIU hCG/ml, >99%. Time to result is four minutes. If negative, a urine pregnancy test will be administered bi-weekly thereafter to ensure that a participant is not pregnant
• No severe or acute medical or psychiatric disability preventing safe study participation or making follow-up unlikely.